Stuart Schreiber (L) and Magnet Biomedicine president and CSO Brian Safina
Stuart Schreiber startup launches with $50M to take molecular glue medicines beyond protein degradation
Magnet Biomedicine launched Tuesday morning with $50 million in Series A financing to expand the scope of molecular glues, drugs that link two proteins together …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.